Stryker Cuts Full-Year Outlook To 6.5% To 7% Organic Growth As Hip And Knee Market Slows
CEO Kevin Lobo, on his last call in the job, said a weaker market and distracted sales teams left Stryker short of its own expectations.
Stryker, the medical device maker, now expects full-year organic sales growth of 6.5% to 7%, Chief Financial Officer Preston Wells said on the company's third-quarter earnings call Thursday. Chair and CEO Kevin Lobo, on his final call before Spencer Stiles takes over, said a hip and knee slowdown and a distracted sales force explain a quarter that "fell short of our expectations."
A lower guide, a slower market
Wells put adjusted earnings per share for the year at $14.80 to $14.90. He tied the revision to softer hip and knee procedure trends, lingering supply limits in peripheral vascular products and a more cautious stance on capital equipment sales.
Third-quarter organic sales rose 7.7%, with adjusted earnings per share of $3.52, up 10.3% from a year earlier. Wells said US hip sales fell 0.6% and US knee sales grew 1.3%. Lobo said the fourth quarter should show a growth rate similar to the third.
Lobo cited affordability worries over higher premiums and deductibles, more insurance pre-authorization denials, and soft demand in Europe and the Middle East. Asked by a Needham analyst, Wells said Stryker assumes the hip and knee market is growing roughly 2.5% year to date, and that it slowed more in the third quarter.
Cyber, SAP and a distracted sales force
Lobo said Stryker also was not winning at its historical rate. He pointed to the first-quarter cyber incident and a July rollout of SAP software in orthopedics, which delayed order entry and slowed the company's view of market conditions. The slowdown only became clear in early September, he said.
Stryker had been gaining share at a higher rate for the past five or six years, Lobo said, but its teams were distracted and "weren't taking share the way we had been taking share in the past." Of the year overall, he said "certainly it was a surprise for us."
He said the new Mako RPS product is "off to a slow start" because the sales force was distracted, and that incentives are now in place to push it.
Buyback, deals and 2027
Stryker, which sells surgical equipment, implants and the Mako robotic-arm system for joint surgery, repurchased $1 billion of shares in the quarter. Its board authorized another $3 billion, which Wells said leaves room for acquisitions.
The company completed its Zurimed purchase and announced an investment in CMR Surgical, under which Stryker will act as exclusive US sales agent for the Versius robot. Lobo said the plan is to buy CMR eventually.
Stryker will give formal 2027 guidance early next year, though Wells said it expects growth at the high end of its markets. A powered hip impaction tool is due next year. Shares closed Thursday up 2.55%.
Lobo, who called this the last of his 57 earnings calls as CEO, said he "would have preferred to deliver better news."
Sources
- Stryker Lowers Outlook After 3Q Profit Falls — MarketWatch
- Stryker Non-GAAP EPS of $3.52 misses by $0.03, revenue of $6.52B misses by $100M (NYSE:SYK) | Seeking Alpha — seekingalpha.com
- Stryker: Q3 Earnings Snapshot | 9news.com — Associated Press
- Stryker: Q3 Earnings Snapshot | wusa9.com — Associated Press
- SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds? — Yahoo Finance